Università degli Studi di Pavia, Pavia, Italy; Prédicteurs moléculaires et nouvelles cibles en oncologie, INSERM Unit 981, Gustave Roussy, Villejuif, France.
Prédicteurs moléculaires et nouvelles cibles en oncologie, INSERM Unit 981, Gustave Roussy, Villejuif, France.
Crit Rev Oncol Hematol. 2021 Jan;157:103193. doi: 10.1016/j.critrevonc.2020.103193. Epub 2020 Dec 10.
We systematically reviewed the literature regarding short- and long-term safety and tolerability of prophylactic use of Granulocyte-Colony Stimulating Factor (G-CSF) for chemotherapy-related febrile neutropenia (FN).
730 pertinent records published from 1994 to 2020 were identified. Exclusion criteria included no assessment of safety or Quality of life (QOL).
Among 88 full-texts included, most studies were conducted during or shortly after G-CSF administration. Mild-to-moderate medullary bone pain was the most reported side effect, usually responsive to anti-inflammatory drugs although potentially impactful on daily functioning. Transient leukocytosis, thrombocytopenia and alterations in biochemistry were also commonly reported. Short-term improvements in patient-reported outcomes were observed as a result of reduction of FN and secondary complications. Secondary myeloid neoplasms were the only reported late effect. No studies evaluated the long-term impact on QOL.
G-CSF seem safe and well-tolerated, although few data are available on long-term impact of use of G-CSF.
我们系统地回顾了关于预防性使用粒细胞集落刺激因子（G-CSF）预防化疗相关发热性中性粒细胞减少症（FN）的短期和长期安全性和耐受性的文献。
从 1994 年到 2020 年共确定了 730 篇相关记录。排除标准包括未评估安全性或生活质量（QOL）。
在纳入的 88 篇全文中，大多数研究是在 G-CSF 给药期间或之后不久进行的。骨髓骨痛是最常见的副作用，通常对抗炎药有反应，尽管可能对日常功能有影响。短暂性白细胞增多、血小板减少和生化改变也常被报道。由于 FN 和继发并发症的减少，观察到患者报告结果的短期改善。仅报道了继发性髓系肿瘤这一迟发性效应。没有研究评估对 QOL 的长期影响。
G-CSF 似乎是安全且耐受良好的，尽管关于 G-CSF 使用的长期影响的数据很少。
